Clinical Trial Update: Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of adagrasib and nab-sirolimus in patients with advanced solid tumors and KRAS G12C-mutant non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Neoplastic Disease
• Non-small Cell Lung Cancer

Drugs mentioned

• Adagrasib (adagrasib)
• nab-sirolimus (sirolimus (nanoparticle albumin-bound formulation))

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Solid Tumor, Adult, NSCLC | Phase 1 | Status: TERMINATED